메뉴 건너뛰기




Volumn , Issue , 2013, Pages 1199-1266

Cancer and chemotherapy

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84971351755     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter
Times cited : (9)

References (222)
  • 1
    • 84971236837 scopus 로고    scopus 로고
    • Oncogenes and suppressor genes: genetic control of cancer
    • In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
    • Liu ET. Oncogenes and suppressor genes: genetic control of cancer. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1108-1116.
    • (2004) Cecil Textbook of Medicine , pp. 1108-1116
    • Liu, E.T.1
  • 2
    • 84971203121 scopus 로고    scopus 로고
    • Principles of cancer therapy
    • In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
    • Bertino JR, Hait W. Principles of cancer therapy. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1137-1150.
    • (2004) Cecil Textbook of Medicine , pp. 1137-1150
    • Bertino, J.R.1    Hait, W.2
  • 3
    • 80053483803 scopus 로고    scopus 로고
    • Cancer treatment and chemotherapy
    • In: DiPiro JT, Talbert RL, Yee GC, et al., eds. 7th ed. New York: McGraw-Hill
    • Medina PJ, Fausel C. Cancer treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. New York: McGraw-Hill, 2008:2085-2119.
    • (2008) Pharmacotherapy: A Pathophysiologic Approach , pp. 2085-2119
    • Medina, P.J.1    Fausel, C.2
  • 5
    • 84928208788 scopus 로고    scopus 로고
    • Invasion and metastases
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Minn AJ, Massague J. Invasion and metastases. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:117-118.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 117-118
    • Minn, A.J.1    Massague, J.2
  • 6
    • 0017401820 scopus 로고
    • The historical development of cancer chemotherapy
    • Burchenal JH. The historical development of cancer chemotherapy. Semin Oncol 1977;4:135-146.
    • (1977) Semin Oncol , vol.4 , pp. 135-146
    • Burchenal, J.H.1
  • 7
    • 34147147676 scopus 로고
    • General review of cancer therapy
    • In: Moulton FR, ed. Washington, DC: AAAS
    • Woglom WH. General review of cancer therapy. In: Moulton FR, ed. Approaches to Tumor Chemotherapy. Washington, DC: AAAS, 1947:1.
    • (1947) Approaches to Tumor Chemotherapy. , pp. 1
    • Woglom, W.H.1
  • 8
    • 84971339566 scopus 로고    scopus 로고
    • Pharmacology of cancer chemotherapy: drug development
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Sznol M. Pharmacology of cancer chemotherapy: drug development. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:385-392.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 385-392
    • Sznol, M.1
  • 9
    • 84971315765 scopus 로고    scopus 로고
    • Telomeres, telomerase, and cell immortalization
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Wong K-K, Sharpless NE, Depinho RA. Telomeres, telomerase, and cell immortalization. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:53-66.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 53-66
    • Wong, K.-K.1    Sharpless, N.E.2    Depinho, R.A.3
  • 10
    • 84971252552 scopus 로고    scopus 로고
    • Pharmacogenomics
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • El-Khoueiry A, Lenz HJ. Pharmacogenomics. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:402-407.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 402-407
    • El-Khoueiry, A.1    Lenz, H.J.2
  • 11
    • 0003964363 scopus 로고    scopus 로고
    • Accessed December
    • American Cancer Society. Cancer facts and figures, 2010. http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/document/ acspc-026238.pdf. Accessed December 2, 2010.
    • (2010) Cancer facts figures , vol.2 , pp. 2010
  • 12
    • 65249088196 scopus 로고    scopus 로고
    • Epidemiology of cancer
    • In: Goldman L, Ausiello D, eds. 22nd ed. Philadelphia: W.B. Saunders
    • Blot WJ. Epidemiology of cancer. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. Philadelphia: W.B. Saunders, 2004:1116-1120.
    • (2004) Cecil Textbook of Medicine , pp. 1116-1120
    • Blot, W.J.1
  • 13
    • 84971252555 scopus 로고    scopus 로고
    • Accessed December
    • The signs of cancer. http://www.radoncgroup.com/signsofcancer.pdf. Accessed December 16, 2010.
    • (2010) , vol.16
  • 14
    • 84971252554 scopus 로고    scopus 로고
    • Etiology of cancer: viruses: RNA viruses
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Buchschacher GL Jr, Wong-Staal F. Etiology of cancer: viruses: RNA viruses. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:169-177.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 169-177
    • Buchschacher G.L, Jr.1    Wong-Staal, F.2
  • 15
    • 84971212926 scopus 로고    scopus 로고
    • Etiology of cancer: viruses: DNA viruses
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Howley PM, Ganem D, Kieff E. Etiology of cancer: viruses: DNA viruses. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:177-189.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 177-189
    • Howley, P.M.1    Ganem, D.2    Kieff, E.3
  • 16
    • 0032849465 scopus 로고    scopus 로고
    • The chemistry of the metabolites of cyclophosphamide
    • Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 1999;5:627-643.
    • (1999) Curr Pharm Des , vol.5 , pp. 627-643
    • Ludeman, S.M.1
  • 17
    • 0017360366 scopus 로고
    • Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro
    • Goldenberg GJ, Lee M, Lam HY, et al. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 1977;37:755-760.
    • (1977) Cancer Res , vol.37 , pp. 755-760
    • Goldenberg, G.J.1    Lee, M.2    Lam, H.Y.3
  • 18
    • 77954663766 scopus 로고    scopus 로고
    • Bendamustine: something old, something new
    • Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413-423.
    • (2010) Cancer Chemother Pharmacol , vol.66 , pp. 413-423
    • Tageja, N.1    Nagi, J.2
  • 19
    • 77953441848 scopus 로고    scopus 로고
    • Bendamustine: new perspective for an old drug in lymphoproliferative disorders
    • Montillo M, Ricci F, Tedeschi A, et al. Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Rev Hematol 2010;3:131-148.
    • (2010) Expert Rev Hematol , vol.3 , pp. 131-148
    • Montillo, M.1    Ricci, F.2    Tedeschi, A.3
  • 20
    • 77954843368 scopus 로고    scopus 로고
    • Oxazaphosphorines: new therapeutic strategies for an old class of drugs
    • Giraud B, Herbert G, Deroussent A, et al. Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opin Drug Metab Toxicol 2010;6:919-938.
    • (2010) Expert Opin Drug Metab Toxicol , vol.6 , pp. 919-938
    • Giraud, B.1    Herbert, G.2    Deroussent, A.3
  • 21
    • 0033951849 scopus 로고    scopus 로고
    • Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide
    • Huang A, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59:961-972.
    • (2000) Biochem Pharmacol , vol.59 , pp. 961-972
    • Huang, A.1    Roy, P.2    Waxman, D.J.3
  • 22
    • 0024334410 scopus 로고
    • The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo
    • Lind MJ, McGown AT, Hadfield JA, et al. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989;38:1835-1840.
    • (1989) Biochem Pharmacol , vol.38 , pp. 1835-1840
    • Lind, M.J.1    McGown, A.T.2    Hadfield, J.A.3
  • 23
    • 0029008311 scopus 로고
    • Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide
    • Ramu K, Fraiser LH, Mamiya B, et al. Acrolein mercapturates: synthesis, characterization and assessment of their role in the bladder toxicity of cyclophosphamide. Chem Res Toxicol 1995;8:515-524.
    • (1995) Chem Res Toxicol , vol.8 , pp. 515-524
    • Ramu, K.1    Fraiser, L.H.2    Mamiya, B.3
  • 24
    • 0030273743 scopus 로고    scopus 로고
    • Studies on the basis for the toxicity of acrolein mercapturates
    • Ramu K, Perry CS, Ahmed T, et al. Studies on the basis for the toxicity of acrolein mercapturates. Toxicol Appl Pharmacol 1996;140;487-498.
    • (1996) Toxicol Appl Pharmacol , vol.140 , pp. 487-498
    • Ramu, K.1    Perry, C.S.2    Ahmed, T.3
  • 25
    • 0031041912 scopus 로고    scopus 로고
    • Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo
    • Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997;17:75-79.
    • (1997) J Appl Toxicol , vol.17 , pp. 75-79
    • Springate, J.E.1
  • 26
    • 0033051029 scopus 로고    scopus 로고
    • Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles
    • Roy P, Yu LJ, Crespi CL, et al. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999;27:655-666.
    • (1999) Drug Metab Dispos , vol.27 , pp. 655-666
    • Roy, P.1    Yu, L.J.2    Crespi, C.L.3
  • 27
    • 0034711384 scopus 로고    scopus 로고
    • Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites
    • Woodland D, Ito S, Granvil CP, et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-117.
    • (2000) Life Sci , vol.68 , pp. 109-117
    • Woodland, D.1    Ito, S.2    Granvil, C.P.3
  • 28
    • 59649125837 scopus 로고    scopus 로고
    • New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity
    • Storme T, Deroussent A, Mercier L, et al. New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity. J Pharmacol Exp Ther 2009;328:598-609.
    • (2009) J Pharmacol Exp Ther , vol.328 , pp. 598-609
    • Storme, T.1    Deroussent, A.2    Mercier, L.3
  • 29
    • 77955771137 scopus 로고    scopus 로고
    • Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations
    • Kheffache D, Ouameraldi O. Some physicochemical properties of the antitumor drug thiotepa and its metabolite tepa as obtained by density functional theory (DFT) calculations. J Mol Model 2010;16:1383-1390.
    • (2010) J Mol Model , vol.16 , pp. 1383-1390
    • Kheffache, D.1    Ouameraldi, O.2
  • 30
    • 0022898266 scopus 로고
    • DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitroso compounds
    • Eisenbrand G, Muller N, Denkel E, et al. DNA adducts and DNA damage by antineoplastic and carcinogenic N-nitroso compounds. J Cancer Res Clin Oncol 1986;112:196-204.
    • (1986) J Cancer Res Clin Oncol , vol.112 , pp. 196-204
    • Eisenbrand, G.1    Muller, N.2    Denkel, E.3
  • 31
    • 58849156422 scopus 로고    scopus 로고
    • BCNU sequestration by metallothioneines may contribute to resistance in a medulloblastoma cell line
    • Bacolod MD, Fehdrau R, Johnson SP, et al. BCNU sequestration by metallothioneines may contribute to resistance in a medulloblastoma cell line. Cancer Chemother Pharmacol 2009;63:753-758.
    • (2009) Cancer Chemother Pharmacol , vol.63 , pp. 753-758
    • Bacolod, M.D.1    Fehdrau, R.2    Johnson, S.P.3
  • 32
    • 0030866921 scopus 로고    scopus 로고
    • DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance
    • Kyrtopoulos SA, Anderson LM, Chhabra SK, et al. DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. Cancer Detect Prev 1997;21:391-405.
    • (1997) Cancer Detect Prev , vol.21 , pp. 391-405
    • Kyrtopoulos, S.A.1    Anderson, L.M.2    Chhabra, S.K.3
  • 33
    • 0036015562 scopus 로고    scopus 로고
    • Tumour cytochrome P450 and drug activation
    • Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-1347.
    • (2002) Curr Pharm Des , vol.8 , pp. 1335-1347
    • Patterson, L.H.1    Murray, G.I.2
  • 34
    • 0021992540 scopus 로고
    • Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine)
    • Moloney SJ, Wiebkin P, Cummings SW, et al. Metabolic activation of the terminal N-methyl group of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine). Carcinogenesis 1985;6:397-401.
    • (1985) Carcinogenesis , vol.6 , pp. 397-401
    • Moloney, S.J.1    Wiebkin, P.2    Cummings, S.W.3
  • 35
    • 0020630971 scopus 로고
    • Studies on the pathway of methane formation from procarbazine, a 2-methylbenzylhydrazine derivative, by rat liver microsomes
    • Moloney SJ, Prough RA. Studies on the pathway of methane formation from procarbazine, a 2-methylbenzylhydrazine derivative, by rat liver microsomes. Arch Biochem Biophys 1983;221:577-584.
    • (1983) Arch Biochem Biophys , vol.221 , pp. 577-584
    • Moloney, S.J.1    Prough, R.A.2
  • 36
    • 0031918603 scopus 로고    scopus 로고
    • Metabolism of dacarbazine by rat liver microsomes: contribution of CYP1A enzymes to dacarbazine N-demethylation
    • Yamagata S, Ohmori S, Suzuki N, et al. Metabolism of dacarbazine by rat liver microsomes: contribution of CYP1A enzymes to dacarbazine N-demethylation. Drug Metab Dispos 1998;26:379-382.
    • (1998) Drug Metab Dispos , vol.26 , pp. 379-382
    • Yamagata, S.1    Ohmori, S.2    Suzuki, N.3
  • 37
    • 78049241028 scopus 로고    scopus 로고
    • Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
    • Cai W, Maldonado NV, Cui W, et al. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 2010;103:1369-1379.
    • (2010) Br J Cancer , vol.103 , pp. 1369-1379
    • Cai, W.1    Maldonado, N.V.2    Cui, W.3
  • 38
    • 0029072902 scopus 로고
    • The role of N-(hydroxymethyl) melamines as antitumour agents: mechanism of action studies
    • Coley HM, Brooks N, Phillips DH, et al. The role of N-(hydroxymethyl) melamines as antitumour agents: mechanism of action studies. Biochem Pharmacol 1995;9:1203-1212.
    • (1995) Biochem Pharmacol , vol.9 , pp. 1203-1212
    • Coley, H.M.1    Brooks, N.2    Phillips, D.H.3
  • 39
    • 0025726126 scopus 로고
    • Hexamethylmelamine: pharmacology and mechanism of action
    • Ames MM. Hexamethylmelamine: pharmacology and mechanism of action. Can Treat Rev 1991;18(Suppl A):3-14.
    • (1991) Can Treat Rev , vol.18 , pp. 3-14
    • Ames, M.M.1
  • 40
    • 77949630054 scopus 로고    scopus 로고
    • Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation
    • Deng SJ, Wang S, Cao J, et al. Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation. Drug Deliv 2010;17:164-170.
    • (2010) Drug Deliv , vol.17 , pp. 164-170
    • Deng, S.J.1    Wang, S.2    Cao, J.3
  • 41
    • 0025801796 scopus 로고
    • DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates
    • Ponti M, Souhami RL, Fox BW, et al. DNA interstrand crosslinking and sequence selectivity of dimethanesulphonates. Br J Cancer 1991;63:743-747.
    • (1991) Br J Cancer , vol.63 , pp. 743-747
    • Ponti, M.1    Souhami, R.L.2    Fox, B.W.3
  • 42
    • 3042633821 scopus 로고    scopus 로고
    • DNA intrastrand cross-link at the 5'-GA- 3' sequence formed by busulfan and its role in the cytotoxic effect
    • Iwamoto T, Hiraku Y, Oikawa S, et al. DNA intrastrand cross-link at the 5'-GA- 3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci 2004;95:454-458.
    • (2004) Cancer Sci , vol.95 , pp. 454-458
    • Iwamoto, T.1    Hiraku, Y.2    Oikawa, S.3
  • 43
    • 41549130929 scopus 로고    scopus 로고
    • Newer cytotoxic agents: attacking cancer broadly
    • Teicher B. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;24:1610-1617.
    • (2008) Clin Cancer Res , vol.24 , pp. 1610-1617
    • Teicher, B.1
  • 44
    • 10644245994 scopus 로고    scopus 로고
    • Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
    • Chaney SG, Campbell SL, Bassett E, et al. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 2005;53:3-11.
    • (2005) Crit Rev Oncol Hematol , vol.53 , pp. 3-11
    • Chaney, S.G.1    Campbell, S.L.2    Bassett, E.3
  • 45
    • 0031864830 scopus 로고    scopus 로고
    • Oxaliplatin: mechanism of action and antineoplastic activity
    • Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(Suppl 5):4-12.
    • (1998) Semin Oncol , vol.25 , pp. 4-12
    • Raymond, E.1    Faivre, S.2    Woynarowski, J.M.3
  • 46
    • 49249083377 scopus 로고    scopus 로고
    • Amifostine protects against cisplatin-induced ototoxicity in children with average risk medulloblastoma
    • Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average risk medulloblastoma. J Clin Oncol 2008;26:3749-3755.
    • (2008) J Clin Oncol , vol.26 , pp. 3749-3755
    • Fouladi, M.1    Chintagumpala, M.2    Ashley, D.3
  • 47
    • 34547100275 scopus 로고    scopus 로고
    • The resurgence of platinum-based cancer chemotherapy
    • Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev 2007;7:573-584.
    • (2007) Nat Rev , vol.7 , pp. 573-584
    • Kelland, L.1
  • 48
    • 0036288984 scopus 로고    scopus 로고
    • The cellular pharmacology of oxaliplatin resistance
    • Mishima M, Samimi G, Kondo A, et al. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002;38:1405-1412.
    • (2002) Eur J Cancer , vol.38 , pp. 1405-1412
    • Mishima, M.1    Samimi, G.2    Kondo, A.3
  • 49
    • 5344266052 scopus 로고    scopus 로고
    • Protein interactions with platinum- DNA adducts: from structure to function
    • Chaney SG, Campbell SL, Temple B, et al. Protein interactions with platinum- DNA adducts: from structure to function. J Inorg Biochem 2004;98:1551-1559.
    • (2004) J Inorg Biochem , vol.98 , pp. 1551-1559
    • Chaney, S.G.1    Campbell, S.L.2    Temple, B.3
  • 50
    • 3042782623 scopus 로고    scopus 로고
    • Cisplatin and related anticancer drugs: recent advances and insights
    • Barnes KR, Lippard SJ. Cisplatin and related anticancer drugs: recent advances and insights. Met Ions Biol Syst 2004;42:143-177.
    • (2004) Met Ions Biol Syst , vol.42 , pp. 143-177
    • Barnes, K.R.1    Lippard, S.J.2
  • 51
    • 23644432241 scopus 로고    scopus 로고
    • New-generation platinum drugs in the treatment of cisplatinresistant cancers
    • McKeage MJ. New-generation platinum drugs in the treatment of cisplatinresistant cancers. Expert Opin Invest Drugs 2005;14:1033-1046.
    • (2005) Expert Opin Invest Drugs , vol.14 , pp. 1033-1046
    • McKeage, M.J.1
  • 52
    • 17444422174 scopus 로고    scopus 로고
    • Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
    • Kweekel DM, Gelderblom H, Guchelaar H-J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
    • (2005) Cancer Treat Rev , vol.31 , pp. 90-105
    • Kweekel, D.M.1    Gelderblom, H.2    Guchelaar, H.-J.3
  • 53
    • 0035003714 scopus 로고    scopus 로고
    • A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels
    • Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltagegated sodium channels. J Neurophysiol 2001;85:2293-2297.
    • (2001) J Neurophysiol , vol.85 , pp. 2293-2297
    • Grolleau, F.1    Gamelin, L.2    Boisdron-Celle, M.3
  • 54
    • 3042523914 scopus 로고    scopus 로고
    • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
    • Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
    • (2004) Clin Cancer Res , vol.10 , pp. 4055-4061
    • Gamelin, L.1    Boisdron-Celle, M.2    Delva, R.3
  • 55
    • 34447525351 scopus 로고    scopus 로고
    • Broadening the clinical use of platinum drug-based chemotherapy with new analogs: satraplatin and picoplatin
    • Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogs: satraplatin and picoplatin. Expert Opin Invest Drugs 2007;16:1009-1021.
    • (2007) Expert Opin Invest Drugs , vol.16 , pp. 1009-1021
    • Kelland, L.1
  • 56
    • 41549164880 scopus 로고    scopus 로고
    • Current status and future prospects for satraplatin, an oral platinum analog
    • Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analog. Clin Cancer Res 2008;14:1633-1638.
    • (2008) Clin Cancer Res , vol.14 , pp. 1633-1638
    • Choy, H.1    Park, C.2    Yao, M.3
  • 57
    • 77954187741 scopus 로고    scopus 로고
    • DNA topoisomerases and their poisoning by anticancer and antibacterial drugs
    • Pommier Y, Leo E, Zhang HL, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol Rev 2010;17:421-433.
    • (2010) Chem Biol Rev , vol.17 , pp. 421-433
    • Pommier, Y.1    Leo, E.2    Zhang, H.L.3
  • 58
    • 35748968504 scopus 로고    scopus 로고
    • DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation
    • Dal Ben D, Palumbo M, Zagotto G, et al. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. Curr Pharm Des 2007;13:2766-2780.
    • (2007) Curr Pharm Des , vol.13 , pp. 2766-2780
    • Dal Ben, D.1    Palumbo, M.2    Zagotto, G.3
  • 59
    • 0037180432 scopus 로고    scopus 로고
    • The mechanism of topoisomerase I poisoning by a camptothecin analog
    • Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci 2002;99:15387-15392.
    • (2002) Proc Natl Acad Sci , vol.99 , pp. 15387-15392
    • Staker, B.L.1    Hjerrild, K.2    Feese, M.D.3
  • 60
    • 77955180152 scopus 로고    scopus 로고
    • Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I-DNA complex
    • Giordano M, D'Annessa I, Coletta A, et al. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I-DNA complex. PLos One 2010;5:e10934.
    • (2010) PLos One , vol.5 , pp. e10934
    • Giordano, M.1    D'Annessa, I.2    Coletta, A.3
  • 61
    • 17144371295 scopus 로고    scopus 로고
    • Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex
    • Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-2345.
    • (2005) J Med Chem , vol.48 , pp. 2336-2345
    • Staker, B.L.1    Feese, M.D.2    Cushman, M.3
  • 63
    • 33244477127 scopus 로고    scopus 로고
    • Topoisomerase interactive agents
    • In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. 7th ed. Baltimore: Lippincott Williams & Wilkins
    • Takimoto CH. Topoisomerase interactive agents. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Baltimore: Lippincott Williams & Wilkins, 2005:375-390.
    • (2005) Cancer: Principles and Practice of Oncology , pp. 375-390
    • Takimoto, C.H.1
  • 64
    • 72949121914 scopus 로고    scopus 로고
    • A comeback for camptothecins
    • Kirschbaum M. A comeback for camptothecins? Leuk Lymph 2009;50:1914-1915.
    • (2009) Leuk Lymph , vol.50 , pp. 1914-1915
    • Kirschbaum, M.1
  • 65
    • 71349085110 scopus 로고    scopus 로고
    • Quantitative structure-property relationships of camptothecins in humans
    • Xu C, Barchet TM, Mager DE. Quantitative structure-property relationships of camptothecins in humans. Cancer Chemother Pharmacol 2009;65:325-333.
    • (2009) Cancer Chemother Pharmacol , vol.65 , pp. 325-333
    • Xu, C.1    Barchet, T.M.2    Mager, D.E.3
  • 66
    • 77950588535 scopus 로고    scopus 로고
    • Cancer therapies using the camptothecins A review of the in vivo literature
    • Venditto VJ, Simanek EE. Cancer therapies using the camptothecins. A review of the in vivo literature. Mol Pharmacol 2010;7:307-349.
    • (2010) Mol Pharmacol , vol.7 , pp. 307-349
    • Venditto, V.J.1    Simanek, E.E.2
  • 67
    • 84855318100 scopus 로고    scopus 로고
    • Pharmacogenetics of irinotecan An ethnicity based prediction of irinotecan adverse effects
    • Shimoyama S. Pharmacogenetics of irinotecan. An ethnicity based prediction of irinotecan adverse effects. World J Gastrointest Surg 2010;2:14-21.
    • (2010) World J Gastrointest Surg , vol.2 , pp. 14-21
    • Shimoyama, S.1
  • 68
    • 65349181626 scopus 로고    scopus 로고
    • UGT1A16 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients
    • Onoue M, Terada T, Kobayashi M, et al. UGT1A16 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136-142.
    • (2009) Int J Clin Oncol , vol.14 , pp. 136-142
    • Onoue, M.1    Terada, T.2    Kobayashi, M.3
  • 69
    • 70849083959 scopus 로고    scopus 로고
    • Development of a highly stable and targetable nanoliposomal formulation of topotecan
    • Drummond DC, Noble CO, Guo Z, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2010;141:13-21.
    • (2010) J Control Release , vol.141 , pp. 13-21
    • Drummond, D.C.1    Noble, C.O.2    Guo, Z.3
  • 70
    • 0141940254 scopus 로고    scopus 로고
    • Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha
    • Vilain N, Tsai-Pflugfelder M, Benoit A, et al. Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha. Nucleic Acids Res 2003;31:5714-5722.
    • (2003) Nucleic Acids Res , vol.31 , pp. 5714-5722
    • Vilain, N.1    Tsai-Pflugfelder, M.2    Benoit, A.3
  • 71
    • 76449107191 scopus 로고    scopus 로고
    • A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II
    • Chee GL, Yalowich JC, Bodner A, et al. A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II. Bioorg Med Chem 2010;18:830-838.
    • (2010) Bioorg Med Chem , vol.18 , pp. 830-838
    • Chee, G.L.1    Yalowich, J.C.2    Bodner, A.3
  • 72
    • 78650517282 scopus 로고    scopus 로고
    • The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIa
    • Naik PK, Dubey A, Soni K, et al. The binding modes and binding affinities of epipodophyllotoxin derivatives with human topoisomerase IIa. J. Molec Graph Model 2010;29:546-564.
    • (2010) J. Molec Graph Model , vol.29 , pp. 546-564
    • Naik, P.K.1    Dubey, A.2    Soni, K.3
  • 73
    • 0032189081 scopus 로고    scopus 로고
    • Secondary leukemias induced by topoisomerase-targeted drugs
    • Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-255.
    • (1998) Biochim Biophys Acta , vol.1400 , pp. 233-255
    • Felix, C.A.1
  • 74
    • 0038813941 scopus 로고    scopus 로고
    • Anthracyclines: selected new developments
    • Binaschi M, Bigioni M, Cipollone A, et al. Anthracyclines: selected new developments. Curr Med Chem 2001;1:113-130.
    • (2001) Curr Med Chem , vol.1 , pp. 113-130
    • Binaschi, M.1    Bigioni, M.2    Cipollone, A.3
  • 75
    • 0033006172 scopus 로고    scopus 로고
    • A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin
    • Gerwirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
    • (1999) Biochem Pharmacol , vol.57 , pp. 727-741
    • Gerwirtz, D.A.1
  • 76
    • 0035871958 scopus 로고    scopus 로고
    • Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs
    • Zunino F, Pratesi G, Perego P. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 2001;61:933-938.
    • (2001) Biochem Pharmacol , vol.61 , pp. 933-938
    • Zunino, F.1    Pratesi, G.2    Perego, P.3
  • 77
    • 6344226473 scopus 로고    scopus 로고
    • Interactions of novel morpholine and hexamethylene derivatives of anthracycline antibiotics with DNA
    • Piestrzeniecwicz MK, Wilmanska D, Szemraj J, et al. Interactions of novel morpholine and hexamethylene derivatives of anthracycline antibiotics with DNA. Z Naturforsch 2004;59:739-748.
    • (2004) Z Naturforsch , vol.59 , pp. 739-748
    • Piestrzeniecwicz, M.K.1    Wilmanska, D.2    Szemraj, J.3
  • 78
    • 41849106072 scopus 로고    scopus 로고
    • Cellular mechanisms of resistance against taxanes and anthracyclines in cancer: intrinsic and acquired
    • Chien AJ, Moasser MM. Cellular mechanisms of resistance against taxanes and anthracyclines in cancer: intrinsic and acquired. Semin Oncol 2008;35(Suppl 2):S1-S14.
    • (2008) Semin Oncol , vol.35 , pp. S1-S14
    • Chien, A.J.1    Moasser, M.M.2
  • 79
    • 5644297293 scopus 로고    scopus 로고
    • Reversal of cancer by green tea polyphenols
    • Mei Y, Qian F, Wei M, et al. Reversal of cancer by green tea polyphenols. J Pharm Pharmacol 2004;56:1307-1314.
    • (2004) J Pharm Pharmacol , vol.56 , pp. 1307-1314
    • Mei, Y.1    Qian, F.2    Wei, M.3
  • 80
    • 0034599915 scopus 로고    scopus 로고
    • Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance
    • Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 2000;114:155-162.
    • (2000) Toxicol Lett , vol.114 , pp. 155-162
    • Sadzuka, Y.1    Sugiyama, T.2    Sonobe, T.3
  • 81
    • 0030889051 scopus 로고    scopus 로고
    • Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug resistant cell lines
    • Stammler G, Volm M. Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug resistant cell lines. Anticancer Drugs 1997;8:265-268.
    • (1997) Anticancer Drugs , vol.8 , pp. 265-268
    • Stammler, G.1    Volm, M.2
  • 82
    • 1642576976 scopus 로고    scopus 로고
    • Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents
    • Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors and lysosomotropic agents. Mol Pharmacol 2004;65:181-195.
    • (2004) Mol Pharmacol , vol.65 , pp. 181-195
    • Kwok, J.C.1    Richardson, D.R.2
  • 83
    • 67650233909 scopus 로고    scopus 로고
    • New developments in anthracycline- induced cardiotoxicity
    • Mordente A, Meucci E, Silvestrini GE, et al. New developments in anthracycline- induced cardiotoxicity. Curr Med Chem 2009;16:1656-1672.
    • (2009) Curr Med Chem , vol.16 , pp. 1656-1672
    • Mordente, A.1    Meucci, E.2    Silvestrini, G.E.3
  • 84
    • 0035190606 scopus 로고    scopus 로고
    • Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road
    • Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: cytoplasmic versus nuclear-a fork in the road. Drug Res Updates 2001;4:169-177.
    • (2001) Drug Res Updates , vol.4 , pp. 169-177
    • Lothstein, L.1    Israel, M.2    Sweatman, T.W.3
  • 85
    • 0742269397 scopus 로고    scopus 로고
    • The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
    • Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130:1-7.
    • (2004) J Cancer Res Clin Oncol , vol.130 , pp. 1-7
    • Swain, S.M.1    Vici, P.2
  • 86
    • 1842559586 scopus 로고    scopus 로고
    • The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
    • Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004;18:664-675.
    • (2004) FASEB J , vol.18 , pp. 664-675
    • Fogli, S.1    Nieri, P.2    Breschi, M.C.3
  • 87
    • 52949118777 scopus 로고    scopus 로고
    • Carbonyl reductase 1 is a predominant doxorubicin reductase in human liver
    • Kassner N, Huse K, Martin HJ, et al. Carbonyl reductase 1 is a predominant doxorubicin reductase in human liver. Drug Metab Dispos 2008;36:2113-2120.
    • (2008) Drug Metab Dispos , vol.36 , pp. 2113-2120
    • Kassner, N.1    Huse, K.2    Martin, H.J.3
  • 88
    • 42049114942 scopus 로고    scopus 로고
    • Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes
    • Yamashita T, Fukushima T, Ueda T. Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes. Leuk Lymph 2008;49:809-814.
    • (2008) Leuk Lymph , vol.49 , pp. 809-814
    • Yamashita, T.1    Fukushima, T.2    Ueda, T.3
  • 89
    • 39049089593 scopus 로고    scopus 로고
    • The use of dexrazoxane for the prevention of anthracycline extravasation injury
    • Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. Expert Opin Invest Drugs 2008;17:217-223.
    • (2008) Expert Opin Invest Drugs , vol.17 , pp. 217-223
    • Hasinoff, B.B.1
  • 90
    • 74049111479 scopus 로고    scopus 로고
    • Predicting anthracycline benefit: have we made any progress
    • Moretti E, Oakman C, Di Leo A. Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol 2009;21:507-515.
    • (2009) Curr Opin Oncol , vol.21 , pp. 507-515
    • Moretti, E.1    Oakman, C.2    Di Leo, A.3
  • 91
    • 0035164058 scopus 로고    scopus 로고
    • A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles
    • Waterhouse DN, Tardi PG, Mayer LD, et al. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001;24:903-920.
    • (2001) Drug Saf , vol.24 , pp. 903-920
    • Waterhouse, D.N.1    Tardi, P.G.2    Mayer, L.D.3
  • 92
    • 69249111858 scopus 로고    scopus 로고
    • Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle invasive bladder cancer
    • Grossman HB, O'Donnell MA, Cookson MS, et al. Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle invasive bladder cancer. Rev Urol 2008;10:281-289.
    • (2008) Rev Urol , vol.10 , pp. 281-289
    • Grossman, H.B.1    O'Donnell, M.A.2    Cookson, M.S.3
  • 93
    • 0037291073 scopus 로고    scopus 로고
    • Caffeine enhances the myocardial uptake of idarubicin but reverses its negative inotropic effect
    • Kang W, Weiss M. Caffeine enhances the myocardial uptake of idarubicin but reverses its negative inotropic effect. Naunyn Schmiedelbergs Arch Pharmacol 2003;367:151-155.
    • (2003) Naunyn Schmiedelbergs Arch Pharmacol , vol.367 , pp. 151-155
    • Kang, W.1    Weiss, M.2
  • 94
    • 17044391471 scopus 로고    scopus 로고
    • Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta
    • Correale J, Rush C, Amengual A, et al. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J Neuroimmunol 2005;162:173-183.
    • (2005) J Neuroimmunol , vol.162 , pp. 173-183
    • Correale, J.1    Rush, C.2    Amengual, A.3
  • 95
    • 68249084554 scopus 로고    scopus 로고
    • Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder
    • Kang H-J, Park H-J. Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder. Biochemistry 2009;48:7392-7398.
    • (2009) Biochemistry , vol.48 , pp. 7392-7398
    • Kang, H.-J.1    Park, H.-J.2
  • 96
    • 12144287215 scopus 로고    scopus 로고
    • The immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy
    • Basu S, Brown JE, Flannigan GM, et al. The immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 2004;109:703-709.
    • (2004) Int J Cancer , vol.109 , pp. 703-709
    • Basu, S.1    Brown, J.E.2    Flannigan, G.M.3
  • 97
    • 0037373090 scopus 로고    scopus 로고
    • NAD(P)H:quinone oxidoreductase 1 expression in kidney podocytes
    • Zappa F, Ward T, Pedrinis E, et al. NAD(P)H:quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem 2003;51:297-302.
    • (2003) J Histochem Cytochem , vol.51 , pp. 297-302
    • Zappa, F.1    Ward, T.2    Pedrinis, E.3
  • 98
    • 77953486102 scopus 로고    scopus 로고
    • Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs
    • Snodgrass RG, Collier AC, Coon AE, et al. Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs. J Biol Chem 2010;285:19068-19075.
    • (2010) J Biol Chem , vol.285 , pp. 19068-19075
    • Snodgrass, R.G.1    Collier, A.C.2    Coon, A.E.3
  • 99
    • 38949179532 scopus 로고    scopus 로고
    • Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential
    • Colucci MA, Moody CJ, Couch GD. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Org Biomol Chem 2008;6:637-656.
    • (2008) Org Biomol Chem , vol.6 , pp. 637-656
    • Colucci, M.A.1    Moody, C.J.2    Couch, G.D.3
  • 100
    • 51649099040 scopus 로고    scopus 로고
    • Further insights into the mechanism of the reaction of activated bleomycin with DNA
    • Chow MS, Liu LV, Soloman EI. Further insights into the mechanism of the reaction of activated bleomycin with DNA. Proc Natl Acad Sci 2008;105:13241-13245.
    • (2008) Proc Natl Acad Sci , vol.105 , pp. 13241-13245
    • Chow, M.S.1    Liu, L.V.2    Soloman, E.I.3
  • 101
    • 0022000435 scopus 로고
    • Origin and cytotoxic properties of base propenals derived from DNA
    • Grollman AP, Takeshita M, Pillai KMR, et al. Origin and cytotoxic properties of base propenals derived from DNA. Cancer Res 1985;45:1127-1131.
    • (1985) Cancer Res , vol.45 , pp. 1127-1131
    • Grollman, A.P.1    Takeshita, M.2    Pillai, K.M.R.3
  • 102
    • 8444244570 scopus 로고    scopus 로고
    • Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis
    • Brewer GJ, Dick R, Ullenbruch MR, et al. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98:2160-2167.
    • (2004) J Inorg Biochem , vol.98 , pp. 2160-2167
    • Brewer, G.J.1    Dick, R.2    Ullenbruch, M.R.3
  • 103
    • 77956524295 scopus 로고    scopus 로고
    • Angiotensin converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury
    • Li P, Xiao HD, Xu J, et al. Angiotensin converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol 2010;177:1113-1121.
    • (2010) Am J Pathol , vol.177 , pp. 1113-1121
    • Li, P.1    Xiao, H.D.2    Xu, J.3
  • 104
    • 0035988820 scopus 로고    scopus 로고
    • Macropodid herpesvirus 1 encodes genes for both thymidylate synthase and ICP34.5
    • Guliana S, Polkinghorne I, Smith GA, et al. Macropodid herpesvirus 1 encodes genes for both thymidylate synthase and ICP34.5. Virus Genes 2002;24:207-213.
    • (2002) Virus Genes , vol.24 , pp. 207-213
    • Guliana, S.1    Polkinghorne, I.2    Smith, G.A.3
  • 105
    • 0029619543 scopus 로고
    • Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site
    • Schiffer CA, Clifton IJ, Davisson VJ, et al. Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Biochemistry 1995;34:16279-16287.
    • (1995) Biochemistry , vol.34 , pp. 16279-16287
    • Schiffer, C.A.1    Clifton, I.J.2    Davisson, V.J.3
  • 106
    • 77953139949 scopus 로고    scopus 로고
    • Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase
    • Jarmula A, Fraczyk T, Cieplak P, et al. Mechanism of influence of phosphorylation on serine 124 on a decrease of catalytic activity of human thymidylate synthase. Bioorg Med Chem 2010;18:3361-3370.
    • (2010) Bioorg Med Chem , vol.18 , pp. 3361-3370
    • Jarmula, A.1    Fraczyk, T.2    Cieplak, P.3
  • 107
    • 0026794266 scopus 로고
    • Structural basis for recognition of polyglutamyl folates by thymidylate synthase
    • Kamb A, Finer-Moore J, Calvert AH, et al. Structural basis for recognition of polyglutamyl folates by thymidylate synthase. Biochemistry 1992;31:9883-9890.
    • (1992) Biochemistry , vol.31 , pp. 9883-9890
    • Kamb, A.1    Finer-Moore, J.2    Calvert, A.H.3
  • 108
    • 33747169515 scopus 로고    scopus 로고
    • Dihydropyrimidine dehydrogenase defi- ciency: impact of pharmacogenetics on 5-fluorouracil therapy
    • Lee A, Ezzeldin H, Fourie J, et al. Dihydropyrimidine dehydrogenase defi- ciency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004;2:527-532.
    • (2004) Clin Adv Hematol Oncol , vol.2 , pp. 527-532
    • Lee, A.1    Ezzeldin, H.2    Fourie, J.3
  • 109
    • 33749350447 scopus 로고    scopus 로고
    • Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared to Caucasians
    • Mattison LK, Fourie J, Desmond RA, et al. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared to Caucasians. Cancer Ther Clin 2006;12:5491-5495.
    • (2006) Cancer Ther Clin , vol.12 , pp. 5491-5495
    • Mattison, L.K.1    Fourie, J.2    Desmond, R.A.3
  • 110
    • 33748501145 scopus 로고    scopus 로고
    • Antimetabolites
    • In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. 7th ed. Baltimore: Lippincott Williams & Wilkins
    • Kummar S, Noronha V, Chu E. Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 7th ed. Baltimore: Lippincott Williams & Wilkins, 2005:365-374.
    • (2005) Cancer: Principles and Practice of Oncology , pp. 365-374
    • Kummar, S.1    Noronha, V.2    Chu, E.3
  • 111
    • 84961978282 scopus 로고    scopus 로고
    • Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase
    • Dummins PL, Gready JE. Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase. J Am Chem Soc 2001;123:3418-3428.
    • (2001) J Am Chem Soc , vol.123 , pp. 3418-3428
    • Dummins, P.L.1    Gready, J.E.2
  • 112
    • 0027080589 scopus 로고
    • Crystal structure determination at 2.3 angstrom of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-?-tetrazole
    • Cody V, Luft JR, Ciszak E, et al. Crystal structure determination at 2.3 angstrom of recombinant human dihydrofolate reductase ternary complex with NADPH and methotrexate-?-tetrazole. Anticancer Drug Des 1992;7:483-491.
    • (1992) Anticancer Drug Des , vol.7 , pp. 483-491
    • Cody, V.1    Luft, J.R.2    Ciszak, E.3
  • 113
    • 0030875357 scopus 로고    scopus 로고
    • Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate
    • Cannon WR, Garrison BJ, Benkovic SJ. Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate. J Mol Biol 1997;271:656-668.
    • (1997) J Mol Biol , vol.271 , pp. 656-668
    • Cannon, W.R.1    Garrison, B.J.2    Benkovic, S.J.3
  • 114
    • 0028924642 scopus 로고
    • Contributions of tryptophan 24 and glutamate 30 to binding long-lived water molecules in the ternary complex of human dihydrofolate reductase with methotrexate and NADPH studies by site directed mutagenesis and nuclear magnetic resonance spectroscopy
    • Meiering EM, Li H, Delcamp TJ, et al. Contributions of tryptophan 24 and glutamate 30 to binding long-lived water molecules in the ternary complex of human dihydrofolate reductase with methotrexate and NADPH studies by site directed mutagenesis and nuclear magnetic resonance spectroscopy. J Mol Biol 1995;241:309-325.
    • (1995) J Mol Biol , vol.241 , pp. 309-325
    • Meiering, E.M.1    Li, H.2    Delcamp, T.J.3
  • 116
    • 77949435506 scopus 로고    scopus 로고
    • The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
    • Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Topics 2010;11:37-47.
    • (2010) Curr Drug Topics , vol.11 , pp. 37-47
    • Joerger, M.1    Omlin, A.2    Cerny, T.3
  • 117
    • 33646338595 scopus 로고    scopus 로고
    • Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy
    • Villela LR, Stanford BL, Shah SR. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006;26:641-654.
    • (2006) Pharmacotherapy , vol.26 , pp. 641-654
    • Villela, L.R.1    Stanford, B.L.2    Shah, S.R.3
  • 118
    • 0032950347 scopus 로고    scopus 로고
    • Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis
    • Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26(Suppl 6):42-47.
    • (1999) Semin Oncol , vol.26 , pp. 42-47
    • Mendelsohn, L.G.1    Shih, C.2    Chen, V.J.3
  • 119
    • 0035798375 scopus 로고    scopus 로고
    • Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases
    • Sayre PH, Finer-Moore JS, Fritz TA, et al. Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases. J Mol Biol 2001;313:813-829.
    • (2001) J Mol Biol , vol.313 , pp. 813-829
    • Sayre, P.H.1    Finer-Moore, J.S.2    Fritz, T.A.3
  • 120
    • 0036673489 scopus 로고    scopus 로고
    • Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantition of drug interactions in human HT29 colon cancer cells
    • Raymond E, Louvet C, Tournigand C, et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantition of drug interactions in human HT29 colon cancer cells. Int J Oncol 2002;21:361-367.
    • (2002) Int J Oncol , vol.21 , pp. 361-367
    • Raymond, E.1    Louvet, C.2    Tournigand, C.3
  • 121
    • 78049426102 scopus 로고    scopus 로고
    • ABCC11/MRP8 confers pemetrexed resistance in lung cancer
    • Uemura T, Oguri T, Ozasa H, et al. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci 2010;101:2404-2410.
    • (2010) Cancer Sci , vol.101 , pp. 2404-2410
    • Uemura, T.1    Oguri, T.2    Ozasa, H.3
  • 122
    • 0023521286 scopus 로고
    • 10-Ethyl-10-deaza-aminopterin: strucrtural design and biochemical, pharmacologic, and antitumor properties
    • Sirotnak FM, Schmid GA, Samuels LL, et al. 10-Ethyl-10-deaza-aminopterin: strucrtural design and biochemical, pharmacologic, and antitumor properties. Natl Cancer Inst Monogr 1987;5:127-131.
    • (1987) Natl Cancer Inst Monogr , vol.5 , pp. 127-131
    • Sirotnak, F.M.1    Schmid, G.A.2    Samuels, L.L.3
  • 123
    • 69049101976 scopus 로고    scopus 로고
    • Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers
    • Izbicka E, Diaz A, Streeper R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 2009;64:993-999.
    • (2009) Cancer Chemother Pharmacol , vol.64 , pp. 993-999
    • Izbicka, E.1    Diaz, A.2    Streeper, R.3
  • 124
    • 34848829782 scopus 로고    scopus 로고
    • Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractor cases of T-cell lymphoma
    • O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractor cases of T-cell lymphoma. Br J Haematol 2007;139:425-428.
    • (2007) Br J Haematol , vol.139 , pp. 425-428
    • O'Connor, O.A.1    Hamlin, P.A.2    Portlock, C.3
  • 125
    • 33748908563 scopus 로고    scopus 로고
    • Pralatreate: an emerging new agent with activity in T-cell lymphoma
    • O'Connor OA. Pralatreate: an emerging new agent with activity in T-cell lymphoma. Curr Opin Oncol 2006;18:591-597.
    • (2006) Curr Opin Oncol , vol.18 , pp. 591-597
    • O'Connor, O.A.1
  • 126
    • 46749119475 scopus 로고    scopus 로고
    • Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies
    • Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 2008;11:508-521.
    • (2008) IDrugs , vol.11 , pp. 508-521
    • Molina, J.R.1
  • 127
    • 67650240123 scopus 로고    scopus 로고
    • Pralatrexate, a new hope for aggressive T-cell lymphoma
    • Rueda A, Casanova M, Quero C, et al. Pralatrexate, a new hope for aggressive T-cell lymphoma? Clin Transl Oncol 2009;11:215-220.
    • (2009) Clin Transl Oncol , vol.11 , pp. 215-220
    • Rueda, A.1    Casanova, M.2    Quero, C.3
  • 128
    • 67651202352 scopus 로고    scopus 로고
    • A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma
    • Mould DR, Sweeney K, Duffull SB, et al. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2008;86:190-196.
    • (2008) Clin Pharmacol Ther , vol.86 , pp. 190-196
    • Mould, D.R.1    Sweeney, K.2    Duffull, S.B.3
  • 129
    • 78751474637 scopus 로고    scopus 로고
    • Single agent and combination studies of pralatexate and molecular correlates of sensitivity
    • Serova M, Bieche I, Sablin MP, et al. Single agent and combination studies of pralatexate and molecular correlates of sensitivity. Br J Cancer 2011;104:272-280.
    • (2011) Br J Cancer , vol.104 , pp. 272-280
    • Serova, M.1    Bieche, I.2    Sablin, M.P.3
  • 130
    • 0036082415 scopus 로고    scopus 로고
    • The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs
    • Coulthard SA, Hogarth LA, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharamcol 2002;62:102-109.
    • (2002) Mol Pharamcol , vol.62 , pp. 102-109
    • Coulthard, S.A.1    Hogarth, L.A.2    Little, M.3
  • 131
    • 9144252139 scopus 로고    scopus 로고
    • Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice
    • Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Mont 2004;10:247-254.
    • (2004) Med Sci Mont , vol.10 , pp. 247-254
    • Cara, C.J.1    Pena, A.S.2    Sans, M.3
  • 132
    • 58449111231 scopus 로고    scopus 로고
    • The increasing complexity of mercaptopurine pharmacogenomics
    • Marsh S, Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009;85:139-141.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 139-141
    • Marsh, S.1    Booven, D.J.2
  • 133
    • 34250356290 scopus 로고    scopus 로고
    • Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics
    • Hartford C, Vasquez E, Schwab M, et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007;67:4965-4972.
    • (2007) Cancer Res , vol.67 , pp. 4965-4972
    • Hartford, C.1    Vasquez, E.2    Schwab, M.3
  • 134
    • 58449117037 scopus 로고    scopus 로고
    • Genetic polymorphism of inositol triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for lymphoblastic leukemia
    • Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inositol triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-172.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 164-172
    • Stocco, G.1    Cheok, M.H.2    Crews, K.R.3
  • 136
    • 33750435940 scopus 로고    scopus 로고
    • Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells
    • Fotoohi AK, Lindqvist M, Peterson C, et al. Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells. Nucleosides Nucleotides Nucleic Acids 2006;25:1039-1044.
    • (2006) Nucleosides Nucleotides Nucleic Acids , vol.25 , pp. 1039-1044
    • Fotoohi, A.K.1    Lindqvist, M.2    Peterson, C.3
  • 137
    • 42049091651 scopus 로고    scopus 로고
    • Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
    • Cai J, Damaraju VL, Grouix N, et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008;68:2349-2357.
    • (2008) Cancer Res , vol.68 , pp. 2349-2357
    • Cai, J.1    Damaraju, V.L.2    Grouix, N.3
  • 138
    • 70649100419 scopus 로고    scopus 로고
    • Genetic factors influencing cytarabine therapy
    • Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657-1674.
    • (2009) Pharmacogenomics , vol.10 , pp. 1657-1674
    • Lamba, J.K.1
  • 139
    • 70349490598 scopus 로고    scopus 로고
    • Pentostatin treatment combinations in chronic lymphocytic leukemia
    • Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2009;7:386-392.
    • (2009) Clin Adv Hematol Oncol , vol.7 , pp. 386-392
    • Lamanna, N.1    Kay, N.E.2
  • 140
    • 78650177166 scopus 로고    scopus 로고
    • Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications
    • Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses 2011;76:24-31.
    • (2011) Med Hypotheses , vol.76 , pp. 24-31
    • Kovacic, P.1
  • 141
    • 33646271817 scopus 로고    scopus 로고
    • Novel tubulin-interacting agents: a tale of Taxus brevifolia and Cantharanthus roseus-based drug discovery
    • Chen S-H, Hong J. Novel tubulin-interacting agents: a tale of Taxus brevifolia and Cantharanthus roseus-based drug discovery. Drugs Future 2006;31:123-150.
    • (2006) Drugs Future , vol.31 , pp. 123-150
    • Chen, S.-H.1    Hong, J.2
  • 142
    • 77955080328 scopus 로고    scopus 로고
    • Microtubule-binding natural products for cancer therapy
    • Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med 2010;76:1037-1043.
    • (2010) Planta Med , vol.76 , pp. 1037-1043
    • Yue, Q.X.1    Liu, X.2    Guo, D.A.3
  • 143
    • 77954564134 scopus 로고    scopus 로고
    • Antimicrotubule agents
    • In: DeVita VT Jr, Lawrence TS, Hellman, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Lee JJ, Harris LN. Antimicrotubule agents. In: DeVita VT Jr, Lawrence TS, Hellman, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:447-456.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 447-456
    • Lee, J.J.1    Harris, L.N.2
  • 144
    • 50249139544 scopus 로고    scopus 로고
    • The individualization of cancer therapy: the unexpected role of p53
    • Hait WN, Yang J-M. The individualization of cancer therapy: the unexpected role of p53. Transact Am Clin Climatol Assoc 2006;117:85-101.
    • (2006) Transact Am Clin Climatol Assoc , vol.117 , pp. 85-101
    • Hait, W.N.1    Yang, J.-M.2
  • 145
    • 0141455184 scopus 로고    scopus 로고
    • 3D QSAR studies for the ß-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs) A pseudoreceptor model for taxanes based on the experimental structure of tubulin
    • Maccari L, Manetti F, Corelli, F, et al. 3D QSAR studies for the ß-tubulin binding site of microtubule-stabilizing anticancer agents (MSAAs). A pseudoreceptor model for taxanes based on the experimental structure of tubulin. Il Farmaco 2003;58:659-668.
    • (2003) Il Farmaco , vol.58 , pp. 659-668
    • Maccari, L.1    Manetti, F.2    Corelli, F.3
  • 146
    • 0034850721 scopus 로고    scopus 로고
    • General and recent aspects of the chemistry and structure-activity relationships of taxoids
    • Gueritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr Pharm Des 2001;7:1229-1249.
    • (2001) Curr Pharm Des , vol.7 , pp. 1229-1249
    • Gueritte, F.1
  • 147
    • 0037212671 scopus 로고    scopus 로고
    • Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA
    • Islam MN, Song Y, Iskander MN. Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA. J Mol Graph Model 2003;21:263-272.
    • (2003) J Mol Graph Model , vol.21 , pp. 263-272
    • Islam, M.N.1    Song, Y.2    Iskander, M.N.3
  • 148
    • 0037407830 scopus 로고    scopus 로고
    • 3D QSAR studies of the interaction between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA) A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones
    • Manetti F, Forli S, Maccari L, et al. 3D QSAR studies of the interaction between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones. Il Farmaco 2003;58:357-361.
    • (2003) Il Farmaco , vol.58 , pp. 357-361
    • Manetti, F.1    Forli, S.2    Maccari, L.3
  • 149
    • 1542394399 scopus 로고    scopus 로고
    • 3D QSAR models of interactions between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones
    • Manetti F, Maccari L, Corelli F, et al. 3D QSAR models of interactions between ß-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones. Curr Topics Med Chem 2004;4:203-217.
    • (2004) Curr Topics Med Chem , vol.4 , pp. 203-217
    • Manetti, F.1    Maccari, L.2    Corelli, F.3
  • 150
    • 65249112145 scopus 로고    scopus 로고
    • The tubulin-bound conformation of paclitaxel: T-taxol vs
    • Yang Y, Alcaraz AA, Snyder JP. The tubulin-bound conformation of paclitaxel: T-taxol vs. "PTX-NY." J Natl Prod 2009;72:422-429.
    • (2009) "PTX-NY." J Natl Prod , vol.72 , pp. 422-429
    • Yang, Y.1    Alcaraz, A.A.2    Snyder, J.P.3
  • 151
    • 2442719015 scopus 로고    scopus 로고
    • Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs and minipigs
    • Vaclavikova R, Soucek P, Svobodova L, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs and minipigs. Drug Metab Dispos 2004;32:666-674.
    • (2004) Drug Metab Dispos , vol.32 , pp. 666-674
    • Vaclavikova, R.1    Soucek, P.2    Svobodova, L.3
  • 152
    • 0141993644 scopus 로고    scopus 로고
    • Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants
    • Vaclavikova R, Horsky S, Simek P, et al. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn- Schmiedelbergs Arch Pharmacol 2003;368:200-209.
    • (2003) Naunyn- Schmiedelbergs Arch Pharmacol , vol.368 , pp. 200-209
    • Vaclavikova, R.1    Horsky, S.2    Simek, P.3
  • 153
    • 0036201599 scopus 로고    scopus 로고
    • Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship
    • Cresteil T, Monsarrat B, DuBois J, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;39:438-445.
    • (2002) Drug Metab Dispos , vol.39 , pp. 438-445
    • Cresteil, T.1    Monsarrat, B.2    DuBois, J.3
  • 155
    • 1542380040 scopus 로고    scopus 로고
    • Interation of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity
    • Buey RM, Diaz JF, Andreu JM, et al. Interation of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol 2004;11:225-236.
    • (2004) Chem Biol , vol.11 , pp. 225-236
    • Buey, R.M.1    Diaz, J.F.2    Andreu, J.M.3
  • 156
    • 0038349992 scopus 로고    scopus 로고
    • Epothilone B and its analogs: a new family of anticancer agents
    • Altmann K-H. Epothilone B and its analogs: a new family of anticancer agents. Mini Rev Med Chem 2003;3:149-158.
    • (2003) Mini Rev Med Chem , vol.3 , pp. 149-158
    • Altmann, K.-H.1
  • 157
    • 60849093178 scopus 로고    scopus 로고
    • Discovery of ixabepilone
    • Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009;8:275-281.
    • (2009) Mol Cancer Ther , vol.8 , pp. 275-281
    • Hunt, J.T.1
  • 158
    • 14844338576 scopus 로고    scopus 로고
    • Much anticipated-the bioactive conformation of epothilone and its binding to tubulin
    • Heinz DW, Schubert W-D, Hofle G. Much anticipated-the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed 2005;44:1298-1301.
    • (2005) Angew Chem Int Ed , vol.44 , pp. 1298-1301
    • Heinz, D.W.1    Schubert, W.-D.2    Hofle, G.3
  • 160
    • 2042474777 scopus 로고    scopus 로고
    • Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    • Engles FK, Ten-Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004;75:448-454.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 448-454
    • Engles, F.K.1    Ten-Tije, A.J.2    Baker, S.D.3
  • 161
    • 59449102526 scopus 로고    scopus 로고
    • Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
    • Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-730.
    • (2009) Clin Cancer Res , vol.15 , pp. 723-730
    • Mita, A.C.1    Denis, L.J.2    Rowinsky, E.K.3
  • 162
    • 50849088935 scopus 로고    scopus 로고
    • A multicenter phase II study of XRP2658 administered as a 1-hr i.v infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
    • Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP2658 administered as a 1-hr i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-1552.
    • (2008) Ann Oncol , vol.19 , pp. 1547-1552
    • Pivot, X.1    Koralewski, P.2    Hidalgo, J.L.3
  • 163
    • 77953163579 scopus 로고    scopus 로고
    • XRP6258-induced gene expression patterns in head and neck cancer carcinomas
    • Yoo GH, Kafri Z, Ensley JF, et al. XRP6258-induced gene expression patterns in head and neck cancer carcinomas. Laryngoscope 2010;120:1114-1119.
    • (2010) Laryngoscope , vol.120 , pp. 1114-1119
    • Yoo, G.H.1    Kafri, Z.2    Ensley, J.F.3
  • 164
    • 45549107529 scopus 로고    scopus 로고
    • Epothilones: clinical update and future directions
    • Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology 2008;22:408-416.
    • (2008) Oncology , vol.22 , pp. 408-416
    • Donovan, D.1    Vahdat, L.T.2
  • 165
    • 20044379059 scopus 로고    scopus 로고
    • Review: tubulin function, actions of antitubulin drugs, and new drug development
    • Pellegrini F, Budman DR. Review: tubulin function, actions of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264-273.
    • (2005) Cancer Invest , vol.23 , pp. 264-273
    • Pellegrini, F.1    Budman, D.R.2
  • 166
    • 19544393159 scopus 로고    scopus 로고
    • Structual basis for the regulation of tubulin by vinblastine
    • Gigant B, Wang C, Ravelli RBG, et al. Structual basis for the regulation of tubulin by vinblastine. Nature 2005;435:519-522.
    • (2005) Nature , vol.435 , pp. 519-522
    • Gigant, B.1    Wang, C.2    Ravelli, R.B.G.3
  • 167
    • 0011823211 scopus 로고    scopus 로고
    • Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes and epothiolones
    • In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds. 5th ed. New York: BC Decker Inc.
    • Beck WT, Cass CE, Houghton PJ. Microtubule-targeting anticancer drugs derived from plants and microbes: vinca alkaloids, taxanes and epothiolones. In: Bast RC Jr, Kufe DW, Pollock RE, et al., eds. Cancer Medicine, 5th ed. New York: BC Decker Inc., 2003:680-698.
    • (2003) Cancer Medicine , pp. 680-698
    • Beck, W.T.1    Cass, C.E.2    Houghton, P.J.3
  • 168
    • 9144254574 scopus 로고    scopus 로고
    • Microtubulin binding sites as target for developing anticancer agents
    • Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077-1104.
    • (2004) Mini Rev Med Chem , vol.4 , pp. 1077-1104
    • Islam, M.N.1    Iskander, M.N.2
  • 169
    • 0026327465 scopus 로고
    • Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules
    • Himes RH. Interactions of the catharanthus (vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991;51:257-267.
    • (1991) Pharmacol Ther , vol.51 , pp. 257-267
    • Himes, R.H.1
  • 170
    • 78651110078 scopus 로고    scopus 로고
    • Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia
    • Egbelakin A, Ferguson MJ, MacGill EA. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;56:361-367.
    • (2011) Pediatr Blood Cancer , vol.56 , pp. 361-367
    • Egbelakin, A.1    Ferguson, M.J.2    MacGill, E.A.3
  • 171
    • 4644273573 scopus 로고    scopus 로고
    • Severe bone marrow depression induced by the anticancer herb Cantharanthus roseus
    • Wu ML, Deng JF, Wu JC, et al. Severe bone marrow depression induced by the anticancer herb Cantharanthus roseus. J Toxicol Clin Toxicol 2005;43:667-671.
    • (2005) J Toxicol Clin Toxicol , vol.43 , pp. 667-671
    • Wu, M.L.1    Deng, J.F.2    Wu, J.C.3
  • 172
    • 33645624425 scopus 로고    scopus 로고
    • Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine
    • Beulz-Riche D, Grude P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005;19:545-553.
    • (2005) Fundam Clin Pharmacol , vol.19 , pp. 545-553
    • Beulz-Riche, D.1    Grude, P.2    Puozzo, C.3
  • 173
    • 0033840446 scopus 로고    scopus 로고
    • CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes
    • Jakita J, Kuwabara T, Kobayashi H, et al. CYP3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000;28:1121-1127.
    • (2000) Drug Metab Dispos , vol.28 , pp. 1121-1127
    • Jakita, J.1    Kuwabara, T.2    Kobayashi, H.3
  • 174
    • 0031039994 scopus 로고    scopus 로고
    • Interaction of estramustine with tubulin isotypes
    • Laing N, Dahllof B, Hartley-Asp B, et al. Interaction of estramustine with tubulin isotypes. Biochemistry 1997;36:871-878.
    • (1997) Biochemistry , vol.36 , pp. 871-878
    • Laing, N.1    Dahllof, B.2    Hartley-Asp, B.3
  • 175
    • 67649726156 scopus 로고    scopus 로고
    • Protein kinase inhibitors: contributions from structure to clinical compounds
    • Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Quart Rev Biophys 2009;42:1-40.
    • (2009) Quart Rev Biophys , vol.42 , pp. 1-40
    • Johnson, L.N.1
  • 176
    • 18744394349 scopus 로고    scopus 로고
    • Strategies for the design of potent and selective kinase inhibitors
    • McInnes C, Fisher PM. Strategies for the design of potent and selective kinase inhibitors. Curr Pharm Des 2005;11:1845-1863.
    • (2005) Curr Pharm Des , vol.11 , pp. 1845-1863
    • McInnes, C.1    Fisher, P.M.2
  • 177
    • 77649204688 scopus 로고    scopus 로고
    • Selectively nonselective kinase inhibition: striking the right balance
    • Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 2010;53:1413-1437.
    • (2010) J Med Chem , vol.53 , pp. 1413-1437
    • Morphy, R.1
  • 178
    • 61549138378 scopus 로고    scopus 로고
    • Imatinib and its successors: how modern chemistry has changed drug development
    • Muller BA. Imatinib and its successors: how modern chemistry has changed drug development. Curr Pharm Des 2009;15:120-133.
    • (2009) Curr Pharm Des , vol.15 , pp. 120-133
    • Muller, B.A.1
  • 179
    • 0041466445 scopus 로고    scopus 로고
    • Specific targeted therapy of chronic myelogenous leukemia with imatinib
    • Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-422.
    • (2003) Pharmacol Rev , vol.55 , pp. 401-422
    • Deininger, M.W.N.1    Druker, B.J.2
  • 180
    • 13844251975 scopus 로고    scopus 로고
    • Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
    • Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
    • (2005) Cancer Cell , vol.7 , pp. 129-141
    • Weisberg, E.1    Manley, P.W.2    Breitenstein, W.3
  • 181
    • 77957903356 scopus 로고    scopus 로고
    • New insights into small-molecule inhibitors of Bcr-Abl
    • Schenone S, Bruno O, Radi M, et al. New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 2009;31:1-41.
    • (2009) Med Res Rev , vol.31 , pp. 1-41
    • Schenone, S.1    Bruno, O.2    Radi, M.3
  • 182
    • 55549093089 scopus 로고    scopus 로고
    • Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia
    • Jarkowski A III, Sweeny RP. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Pharmacotherapy 2008;28:1374-1382.
    • (2008) Pharmacotherapy , vol.28 , pp. 1374-1382
    • Jarkowski, A.1    Sweeny, R.P.2
  • 183
    • 33745283618 scopus 로고    scopus 로고
    • The structure of dasatinib (BMS- 354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants
    • Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS- 354825) bound to activated Abl kinase domain elucidates its inhibitory activity against imatinib-resistant Abl mutants. Cancer Res 2006;66:5790-5797.
    • (2006) Cancer Res , vol.66 , pp. 5790-5797
    • Tokarski, J.S.1    Newitt, J.A.2    Chang, C.Y.J.3
  • 184
    • 0028142387 scopus 로고
    • A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
    • Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095.
    • (1994) Science , vol.265 , pp. 1093-1095
    • Fry, D.W.1    Kraker, A.J.2    McMichael, A.3
  • 185
    • 0033061032 scopus 로고    scopus 로고
    • Protein tyrosine kinase inhibitors as novel therapeutic agents
    • Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 1999;82:231-239.
    • (1999) Pharmacol Ther , vol.82 , pp. 231-239
    • Levitzki, A.1
  • 186
    • 41649099467 scopus 로고    scopus 로고
    • Structural insights on how irreversible inhibitors can overcome drug resistance in EGFR
    • Michalczyk A, Kluter S, Rode HB, et al. Structural insights on how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 2008;16:3482-3488.
    • (2008) Bioorg Med Chem , vol.16 , pp. 3482-3488
    • Michalczyk, A.1    Kluter, S.2    Rode, H.B.3
  • 187
    • 77951983285 scopus 로고    scopus 로고
    • Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode
    • Kettle JG, Ward RA. Toward the comprehensive systematic enumeration and synthesis of novel kinase inhibitors based on a 4-anilinoquinazoline binding mode. J Chem Inf Model 2010;50:525-533.
    • (2010) J Chem Inf Model , vol.50 , pp. 525-533
    • Kettle, J.G.1    Ward, R.A.2
  • 188
    • 36749034794 scopus 로고    scopus 로고
    • Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, kit, plateletderived growth factor receptor, ras
    • Erman M. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, kit, plateletderived growth factor receptor, ras. J BUON 2007;12(Suppl 1):S83-S94.
    • (2007) J BUON , vol.12 , pp. S83-S94
    • Erman, M.1
  • 189
    • 0030945871 scopus 로고    scopus 로고
    • Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
    • Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997;276:955-960.
    • (1997) Science , vol.276 , pp. 955-960
    • Mohammadi, M.1    McMahon, G.2    Sun, L.3
  • 190
    • 78751559152 scopus 로고    scopus 로고
    • Small-molecule tyrosine kinase inhibitors
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • LoRusso PM, Ryan AJ, Boerner SA, et al. Small-molecule tyrosine kinase inhibitors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:457-468.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 457-468
    • LoRusso, P.M.1    Ryan, A.J.2    Boerner, S.A.3
  • 191
    • 77956868186 scopus 로고    scopus 로고
    • Metabolism considerations for kinase inhibitors in cancer treatment
    • Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin 2010;6:1775-1193.
    • (2010) Expert Opin , vol.6 , pp. 1775-1193
    • Duckett, D.R.1    Cameron, M.D.2
  • 192
    • 70349669267 scopus 로고    scopus 로고
    • Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters
    • Chen HS, Franke R, Orwick S, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-6069.
    • (2009) Clin Cancer Res , vol.15 , pp. 6062-6069
    • Chen, H.S.1    Franke, R.2    Orwick, S.3
  • 194
    • 34547459725 scopus 로고    scopus 로고
    • Sorafenib and sunitinib: novel targeted therapies for renal cell cancer
    • Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-1144.
    • (2007) Pharmacotherapy , vol.27 , pp. 1125-1144
    • Grandinetti, C.A.1    Goldspiel, B.R.2
  • 195
    • 38949140475 scopus 로고    scopus 로고
    • Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma protein expression
    • Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma protein expression. Biomed Pharmacother 2008;62:85-93.
    • (2008) Biomed Pharmacother , vol.62 , pp. 85-93
    • Vinodhkumar, R.1    Song, Y.S.2    Devaki, T.3
  • 196
    • 84895290964 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors and demethylating agents
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Gore SD, Baylin SB, Herman JG. Histone deacetylase inhibitors and demethylating agents. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:477-485.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 477-485
    • Gore, S.D.1    Baylin, S.B.2    Herman, J.G.3
  • 197
    • 49849103540 scopus 로고    scopus 로고
    • Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
    • Newbold A, Lindemann RK, Cluse LA, et al. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008;7:1066-1079.
    • (2008) Mol Cancer Ther , vol.7 , pp. 1066-1079
    • Newbold, A.1    Lindemann, R.K.2    Cluse, L.A.3
  • 198
    • 77954879663 scopus 로고    scopus 로고
    • Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma
    • Whittaker SJ, Demierre M-F, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-4491.
    • (2010) J Clin Oncol , vol.28 , pp. 4485-4491
    • Whittaker, S.J.1    Demierre, M.-F.2    Kim, E.J.3
  • 199
    • 33750306385 scopus 로고    scopus 로고
    • Stability studies of vorinostat and its two metabolites in human plasma, serum, and urine
    • Du L, Musson DG, Wang AQ, Stability studies of vorinostat and its two metabolites in human plasma, serum, and urine. J Pharm Biomed Anal 2006;42:556-564.
    • (2006) J Pharm Biomed Anal , vol.42 , pp. 556-564
    • Du, L.1    Musson, D.G.2    Wang, A.Q3
  • 200
    • 84971318543 scopus 로고    scopus 로고
    • Accessed January
    • Zolinza. http://www.zolinza.com/vorinostat/zolinza/consumer/about/actprogram. jsp. Accessed January 9, 2011.
    • (2011) , vol.9
  • 201
    • 36048953657 scopus 로고
    • Phocomelia and internal defects due to thalidomide
    • Lecutier MA. Phocomelia and internal defects due to thalidomide. Br Med J 1962;2:1147-1147.
    • (1962) Br Med J , vol.2 , pp. 1147-1147
    • Lecutier, M.A.1
  • 202
    • 0001960621 scopus 로고    scopus 로고
    • Miscellaneous chemotherapeutic agents
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Copur MS, Rose M, Gettinger SN. Miscellaneous chemotherapeutic agents. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:490-495.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 490-495
    • Copur, M.S.1    Rose, M.2    Gettinger, S.N.3
  • 203
    • 0031580639 scopus 로고    scopus 로고
    • Thalidomide ban to be lifted in the US
    • Rutter T. Thalidomide ban to be lifted in the US. Br Med J 1997;315:699.
    • (1997) Br Med J , vol.315 , pp. 699
    • Rutter, T.1
  • 204
    • 0041412631 scopus 로고    scopus 로고
    • Thalidomide: from teratogen to antiangiogenic
    • Grover JK, Vats K. Thalidomide: from teratogen to antiangiogenic. Indian J Cancer 2001;38:22-32.
    • (2001) Indian J Cancer , vol.38 , pp. 22-32
    • Grover, J.K.1    Vats, K.2
  • 205
    • 51649117633 scopus 로고    scopus 로고
    • A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
    • Von Lillenfeld TM, Hahn AC, Furkert K, et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008;81:247-252.
    • (2008) Eur J Haematol , vol.81 , pp. 247-252
    • Von Lillenfeld, T.M.1    Hahn, A.C.2    Furkert, K.3
  • 206
    • 34848879192 scopus 로고    scopus 로고
    • Review of thalidomide in the treatment of newly diagnosed multiple myeloma
    • Cavello F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manag 2007;3:543-552.
    • (2007) Ther Clin Risk Manag , vol.3 , pp. 543-552
    • Cavello, F.1    Boccadoro, M.2    Palumbo, A.3
  • 207
    • 77955461166 scopus 로고    scopus 로고
    • Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case match-study
    • Offidani M, Leoni P, Bringhen S, et al. Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case match-study. Leuk Lymphoma 2010;51:1444-1449.
    • (2010) Leuk Lymphoma , vol.51 , pp. 1444-1449
    • Offidani, M.1    Leoni, P.2    Bringhen, S.3
  • 208
    • 33747174832 scopus 로고    scopus 로고
    • Thalidomide metabolism and hydrolysis: mechanisms and implications
    • Lepper ER, Smith NF, Cox MC, et al. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 2006;7:677-685.
    • (2006) Curr Drug Metab , vol.7 , pp. 677-685
    • Lepper, E.R.1    Smith, N.F.2    Cox, M.C.3
  • 209
    • 0032922147 scopus 로고    scopus 로고
    • Thalidomide S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide
    • Zeldis JB, Williams BA, Thomas SD, et al. Thalidomide S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-330.
    • (1999) Clin Ther , vol.21 , pp. 319-330
    • Zeldis, J.B.1    Williams, B.A.2    Thomas, S.D.3
  • 210
    • 49749133938 scopus 로고    scopus 로고
    • RevAssist: a comprehensive risk minimization program for preventing fetal exposure to lenalidomide
    • Castaneda CP, Zeldis JB, Feeman J, et al. RevAssist: a comprehensive risk minimization program for preventing fetal exposure to lenalidomide. Drug Saf 2008;31:743-752.
    • (2008) Drug Saf , vol.31 , pp. 743-752
    • Castaneda, C.P.1    Zeldis, J.B.2    Feeman, J.3
  • 211
    • 63949087792 scopus 로고    scopus 로고
    • Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
    • Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 2009;63:1171-1175.
    • (2009) Cancer Chemother Pharmacol , vol.63 , pp. 1171-1175
    • Kumar, G.1    Lau, H.2    Laskin, O.3
  • 212
    • 77249144468 scopus 로고    scopus 로고
    • Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells
    • Bairey O, Vanichkin A, Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol 2010;32:e77-e85.
    • (2010) Int J Lab Hematol , vol.32 , pp. e77-e85
    • Bairey, O.1    Vanichkin, A.2    Shpilberg, O.3
  • 213
    • 70449637501 scopus 로고    scopus 로고
    • Arsenic trioxide as first line treatment for acute promyelocytic leukemia
    • Leu L, Mohassel L. Arsenic trioxide as first line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm 2009;66:1913-1918.
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 1913-1918
    • Leu, L.1    Mohassel, L.2
  • 214
    • 68449096176 scopus 로고    scopus 로고
    • Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells
    • Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 2009;50:974-984.
    • (2009) Leuk Lymphoma , vol.50 , pp. 974-984
    • Dong, H.1    Chen, L.2    Chen, X.3
  • 216
    • 84895322387 scopus 로고    scopus 로고
    • Proteasome inhibitors
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Molineaux CJ, Crews CM. Proteasome inhibitors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:486-490.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 486-490
    • Molineaux, C.J.1    Crews, C.M.2
  • 217
    • 33644845743 scopus 로고    scopus 로고
    • Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
    • Groll M, Berkers CR, Ploegh HL, et al. Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14:451-456.
    • (2006) Structure , vol.14 , pp. 451-456
    • Groll, M.1    Berkers, C.R.2    Ploegh, H.L.3
  • 218
    • 84971263917 scopus 로고    scopus 로고
    • Monoclonal antibodies
    • In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. 8th ed. Baltimore: Lippincott Williams & Wilkins
    • Robinson MK, Borghaci H, Adams GP, et al. Monoclonal antibodies. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Baltimore: Lippincott Williams & Wilkins, 2008:537-548.
    • (2008) Cancer: Principles and Practice of Oncology , pp. 537-548
    • Robinson, M.K.1    Borghaci, H.2    Adams, G.P.3
  • 219
    • 77951936254 scopus 로고    scopus 로고
    • Monoclonal antibodies in the treatment of colorectal cancer: a review
    • Tol J, Punt CJ. Monoclonal antibodies in the treatment of colorectal cancer: a review. Clin Ther 2010;32:437-453.
    • (2010) Clin Ther , vol.32 , pp. 437-453
    • Tol, J.1    Punt, C.J.2
  • 220
    • 48149110374 scopus 로고    scopus 로고
    • The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)
    • Oei AL, Sweep FC, Thomas CM, et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008;32:1145-1157.
    • (2008) Int J Oncol , vol.32 , pp. 1145-1157
    • Oei, A.L.1    Sweep, F.C.2    Thomas, C.M.3
  • 221
    • 34848887261 scopus 로고    scopus 로고
    • Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy
    • Youssoufian H, Hicklin DJ, Rowinsky EK. Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. Clin Cancer Res 2007;13:5544s-5548s.
    • (2007) Clin Cancer Res , vol.13 , pp. 5544s-5548s
    • Youssoufian, H.1    Hicklin, D.J.2    Rowinsky, E.K.3
  • 222
    • 0032824340 scopus 로고    scopus 로고
    • Monoclonal antibodies in cancer treatment: a review of recent progress
    • Alpaugh K, von Mehren M. Monoclonal antibodies in cancer treatment: a review of recent progress. BioDrugs 1999;12:209-236.
    • (1999) BioDrugs , vol.12 , pp. 209-236
    • Alpaugh, K.1    von Mehren, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.